United States securities and exchange commission logo





                          August 11, 2022

       David Campbell, Ph.D.
       Chief Executive Officer
       Janux Therapeutics, Inc.
       10955 Vista Sorrento Parkway, Suite 200
       San Diego, CA 92130

                                                        Re: Janux Therapeutics,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed August 9,
2022
                                                            File No. 333-266720

       Dear Dr. Campbell:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jason
Drory at 202-551-8342 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Kenneth J. Rollins